ACAmélie Ciernik

Amélie Ciernik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amélie Ciernik has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures1 from Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma

    by Egle Ramelyte, Julian Kött, Aleigha R. Lawless, Amélie Ciernik, Isabel Heidrich, Caroline Zellweger, Kamaneh Montazeri, Joanna Mangana, Daniel J. Smit, Sandra N. Freiberger, et al.

  • Open Access

    Supplementary Data1 from Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma

    by Egle Ramelyte, Julian Kött, Aleigha R. Lawless, Amélie Ciernik, Isabel Heidrich, Caroline Zellweger, Kamaneh Montazeri, Joanna Mangana, Daniel J. Smit, Sandra N. Freiberger, et al.

    Supplementary ctDNA measurement data

  • Open Access

    Data from Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma

    by Egle Ramelyte, Julian Kött, Aleigha R. Lawless, Amélie Ciernik, Isabel Heidrich, Caroline Zellweger, Kamaneh Montazeri, Joanna Mangana, Daniel J. Smit, Sandra N. Freiberger, et al.

    Purpose:Circulating tumor DNA (ctDNA) refers to small DNA fragments, shed from tumor cells into the bloodstream. Measuring ctDNA provides a noninvasive tool for real-time disease monitoring. Although ctDNA predicted overall survival (OS) in metastatic uveal melanoma (mUM) treated with tebentafusp, its broader prognostic value across treatment modalities remains unclear. In this study, we assess the prognostic relevance of longitudinal ctDNA detection and mutant allele fraction (MAF) in patients with mUM treated with different modalities.Experimental Design:To assess ctDNA monitoring as a tool in evaluating therapy response and clinical outcomes in patients with mUM, using an IVDR-certified digital PCR assay targeting GNAQQ209 and GNA11Q209 mutations.Results:We analyzed 655 samples from 75 patients with mUM. Absence of detectable ctDNA in baseline samples prior to first-line therapy was associated with improved OS (HR = 0.13; P = 0.02) and progression-free survival (PFS; HR = 0.31; P = 0.008). Similar associations were observed in patients treated with any line of therapy (OS: HR = 0.19, P = 0.002; PFS: HR = 0.27, P = 0.02). Detection of ctDNA within 3 months of therapy initiation was associated with worse outcomes, independent of baseline detection. Furthermore, patients with MAF > 5% any time point had a significantly poorer prognosis compared with patients with MAF < 5% (median OS 4 months vs. 21 months, P < 0.001; median PFS 2.5 months vs. 3.6 months, P = 0.004), emphasizing the added value of quantitative assessment.Conclusions:Both the presence and level of ctDNA at baseline, along with persistence of ctDNA within 3 months of starting of treatment, are strong negative prognostic markers in mUM. These findings support the clinical utility of ctDNA as a noninvasive tool for disease monitoring.

  • Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma

    by Egle Ramelyte, Julian Kött, Aleigha R. Lawless, Amélie Ciernik, Isabel Heidrich, Caroline Zellweger, Kamaneh Montazeri, Joanna Mangana, Daniel J. Smit, Sandra N. Freiberger, et al.

    Purpose: Circulating tumor DNA (ctDNA) refers to small DNA fragments, shed from tumor cells into the bloodstream. Measuring ctDNA provides a noninvasive tool for real-time disease monitoring. Although ctDNA predicted overall survival (OS) in metastatic uveal melanoma (mUM) treated with tebentafusp, its broader prognostic value across treatment modalities remains unclear. In this study, we assess the prognostic relevance of longitudinal ctDNA detection and mutant allele fraction (MAF) in patients with mUM treated with different modalities. Experimental Design: To assess ctDNA monitoring as a tool in evaluating therapy response and clinical outcomes in patients with mUM, using an IVDR-certified digital PCR assay targeting GNAQQ209 and GNA11Q209 mutations. Results: We analyzed 655 samples from 75 patients with mUM. Absence of detectable ctDNA in baseline samples prior to first-line therapy was associated with improved OS (HR = 0.13; P = 0.02) and progression-free survival (PFS; HR = 0.31; P = 0.008). Similar associations were observed in patients treated with any line of therapy (OS: HR = 0.19, P = 0.002; PFS: HR = 0.27, P = 0.02). Detection of ctDNA within 3 months of therapy initiation was associated with worse outcomes, independent of baseline detection. Furthermore, patients with MAF > 5% any time point had a significantly poorer prognosis compared with patients with MAF < 5% (median OS 4 months vs. 21 months, P < 0.001; median PFS 2.5 months vs. 3.6 months, P = 0.004), emphasizing the added value of quantitative assessment. Conclusions: Both the presence and level of ctDNA at baseline, along with persistence of ctDNA within 3 months of starting of treatment, are strong negative prognostic markers in mUM. These findings support the clinical utility of ctDNA as a noninvasive tool for disease monitoring.


  • Open Access

    Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma

    by Amélie Ciernik, Laure Ciernik, Peter Bonczkowitz, Monika Morak, Lucie Heinzerling, Yacine Bennaceur, Aleigha Lawless, Ryan Sullivan, Julian Kött, Christoffer Gebhardt, et al.

    Background: Uveal melanoma (UM) is the most common primary ocular malignancy with a high rate of metastases. While immune checkpoint inhibitors (ICIs), including ipilimumab and nivolumab (ipi + nivo), have shown efficacy in metastatic cutaneous melanoma, their success in metastatic UM (MUM) remains limited. This study evaluates toxicity and outcomes of ipi + nivo in the largest, multicenter MUM cohort. Methods: We analyzed 131 MUM patients treated with ipi + nivo from 2016 to 2024 across 5 international centers. Rates of toxicity, response, and survival outcomes were assessed. Results: Among 131 patients, 37.4% of patients received 4 cycles of ipi + nivo. The most common reason for ipi + nivo discontinuation (31.3%) was toxicity. Of all treated patients, 80.2% experienced immune-related adverse events (irAEs). The overall response rate (ORR) was 16.4%, and the disease control rate (DCR) was 43.4%. Progression-free survival (PFS) was three months, and the median overall survival (OS) was 18 months. Patients receiving ipi + nivo as second-line therapy had lower ORR compared to patients who received ipi + nivo as first-line therapy (P = .04). Patients with exclusively extrahepatic metastases had a better ORR and OS compared to those with hepatic or mixed metastases (P = .02, P = .02, respectively). 20.6% of patients developed eosinophilia during treatment, which was associated with improved median OS (24 months vs 15 months, P = .02). Conclusions: Ipi + nivo shows moderate efficacy and clinically relevant toxicities in patients with MUM. Eosinophilia is a potential prognostic biomarker, that merits further investigation.